Before and After Convalescent Plasma Therapy for Covid-19 Patients at Jemursari Islamic Hospital Perbedaan Kadar D-Dimer Plasma Sebelum dan Sesudah Pemberian Terapi Plasma Konvalesen Pada Pasien Covid-19 di Rumah Sakit Islam Jemursari

Article Sidebar

Picture in here are illustration from public domain image or provided by the author, as part of their works
pdf XML epub plagiarism check
Published: Dec 31, 2021
DOI: https://doi.org/10.21070/medicra.v4i2.1614
Keywords:
Convalescent plasma therapy, Covid-19, D-Dimer

Main Article Content

Notrisia Rachmayanti
Universitas Nahdlatul Ulama Surabaya
Bastiana Bermawi
Universitas Nahdlatul Ulama Surabaya
Gilang Nugraha
Universitas Nahdlatul Ulama Surabaya
Hamiduumajid Ballihg Ballihgoo
Universitas Nahdlatul Ulama Surabaya

Abstract

The World Health Organization declared Covid-19 as a Public Health Emergency of International Concern in January 2020. Treatment options for Covid-19 are still limited, so the health system is looking for a strategy to deal with Covid-19 by using convalescent plasma therapy. This study aims to analyze differences in plasma D-Dimer levels before and after convalescent plasma therapy. This study is an analytic observational study with a retrospective design approach. D-Dimer data were taken from medical records of Covid -19 patients who received convalescent plasma therapy and were treated at Jemursari Islamic Hospital from January to March 2021. A total of 117 patients received convalescent plasma therapy and D-Dimer examinations were performed. Plasma D-Dimer levels were analyzed using statistical tests and the result was p = 0.227. The results of p > 0.05 can be concluded that there is no difference between plasma D-Dimer levels before and after convalescent plasma therapy in Covid-19 patients treated at Jemursari Islamic Hospital.

Article Details

How to Cite
Rachmayanti, N., Bermawi, B., Nugraha, G., & Ballihgoo, H. B. (2021). Before and After Convalescent Plasma Therapy for Covid-19 Patients at Jemursari Islamic Hospital . Medicra (Journal of Medical Laboratory Science/Technology), 4(2), 107-111. https://doi.org/10.21070/medicra.v4i2.1614
Issue
Vol 4 No 2 (2021): December
Section
Articles
Copyright (c) 2021 Notrisia Rachmayanti

References

Agarwal, A., Mukherjee, A., Kumar, G., Chatterjee, P., Bhatnagar, T., & Malhotra, P. (2020). Convalescent Plasma In The Management Of Moderate Covid-19 In Adults In India: Open Label Phase II Multicentre Randomised Controlled Trial (PLACID Trial). British Medical Journal, 371. doi:10.1136/bmj.m3939.
Huang, S., Shen, C., Xia, C., Huang, X., Fu, Y., & Tian, L. (2020). A Retrospective Study On The Effects Of Convalescent Plasma Therapy In 24 Patients Diagnosed With Covid-19 Pneumonia In February And March 2020 At 2 Centers In Wuhan, China. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 26, e928755-1. doi: 10.12659/MSM.928755
Hunt, B. J., & Levi, M. (2020). Re The Source Of Elevated Plasma D‐dimer Levels In COVID‐19 Infection. British Journal of Haematology. Doi:
10.1111/bjh.16907

Joyner, M. J., Carter, R. E., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., Lesser, E. R., Kunze, K. L., Sexton, M. A., Diaz Soto, J. C., Baker, S. E., Shepherd, J., van Helmond, N., Verdun, N. C., Marks, P., van Buskirk, C. M., … Casadevall, A. (2021). Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. The New England journal of medicine, 384(11), 1015–1027. doi: 10.1056/NEJMoa2031893
RECOVERY. (2021). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England), 397(10285), 1637. doi: 10.1016/S0140-6736(21)00897-7.
Rostami, M., & Mansouritorghabeh, H. (2020). D-dimer level in COVID-19 infection: a systematic review. Expert review of hematology, 13(11), 1265-1275. doi: 10.1080/17474086.2020.1831383
Salman, H. O., & Mohamed, H. S. A (2020). Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia, 36(1), 264-272. doi: 10.1080/1110849.2020.1842087
Simonovich, V. A., Burgos Pratx, L. D., Scibona, P., Beruto, M. V., Vallone, M. G., Vázquez, C., Savoy, N., Giunta, D. H., Pérez, L. G., Sánchez, M., Gamarnik, A. V., Ojeda, D. S., Santoro, D. M., Camino, P. J., Antelo, S., Rainero, K., Vidiella, G. P., Miyazaki, E. A., Cornistein, W., Trabadelo, O. A., … PlasmAr Study Group (2021). A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. The New England Journal Of Medicine, 384(7), 619–629. doi: 10.1056/NEJMoa2031304
Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., ... & Hu, B. (2020). D-dimer as a Biomarker For Disease Severity And Mortality In COVID-19 Patients: a Case Control Study. Journal Of Intensive Care, 8(49). doi: 10.1186/s40560-020-00466-z
Rojas, M., Rodríguez, Y., Monsalve, D. M., Acosta-Ampudia, Y., Camacho, B., Gallo, J. E., Rojas-Villarraga, A., Ramírez-Santana, C., Díaz-Coronado, J. C., Manrique, R., Mantilla, R. D., Shoenfeld, Y., & Anaya, J. M. (2020). Convalescent Plasma in Covid-19: Possible Mechanisms of Action. Autoimmunity reviews, 19(7), 102554. doi: 10.1016/j.autrev.2020.102554